Skip to content
February 21, 2024


Investment information for the new generation


Ramm Pharma (RAMM.C) Begins Trials for NettaVet CBD

RAMM Pharma (RAMM.C) has begun its clinical trials studying the efficacy of its proprietary NettaVet pet cannabinoid formulation for the treatment of four pathologies in animals.

“We are, from an academic stand point, very excited to be able to conduct these clinical trials together with RAMM Pharma and the prospects for these novel treatments to improve the quality life of animals,” stated Prof. Dr. Nadia Crosignani, MSc., PhD (UdelaR, Uruguay), lead advisor for the clinical trials.

The trials will be conducted in partnership with Universidad de la Republica de Uruguay in collaboration with leading international experts at Montreal University, University of Buenos Aires, Sao Paulo State University and University of Barcelona. RAMM is an established pharmaceutical and medical product business founded in Montevideo, Uruguay. The Company has developed medically registered and approved plant-derived cannabinoid pharmaceutical products that have been authorized for sale in Uruguay and for compassionate use in several Latin American countries.


With this in mind, NettaLife is a wholly owned subsidiary of RAMM, focused on the production, export and commercialization of pet products, food, pharmaceutical specialties and cosmetic products for animals. With a cannabis market focused on the medical applications of CBD on humans, its refreshing to see some love given to the underdogs. Horrible pun aside, the clinical trials will be evaluating the efficacy of NettaVet cannabinoid formulation for the treatment of the following four pathologies:


  • Chronic Osteoarthritis pain in dogs
  • Chronic Osteoarthritis pain in horses
  • Allergic Dermatitis in dogs
  • Anxiety in dogs

With regards to our beloved canines and horses, these are some of the most common ailments in both species. The announced clinical trials are intended to address these issues as well as find effective treatment solutions for a broad range of ailments in animals. Through the results generated from its extensive studies of cannabinoids on humans, RAMM will be leveraging its expansive knowledge and database to compliment its veterinary research. The Company hopes that the clinical trials will help push NettaVet’s development of specialized CBD veterinary and medicinal products for animals. CBD has already proven to be beneficial in treating pain, inflammation reduction, immune system improvement, skin and fur care, as well as providing cognitive support without harmful side effects.



So how does this look as an investment opportunity? The pet CBD market is expected to be USD $1.7 billion by the end of 2025. This is driven largely by the emergence of more research-based knowledge on CBD’s potential benefits in combination with continued product innovations from CBD companies. As CBD for pets becomes more mainstream, an increasing amount of pet owners are looking for natural alternatives to treat their pets. If you’re not convinced, here are some more stats. According to Grand View Research, the global veterinary medicine market size was estimated at USD $29.2 billion in 2020. Moreover, its expected to expand at a compound annual growth rate of 7.4% from 2021 to 2028.


Needless to say, there’s a lot of love for our fluffball companions and its reassuring to see a company like RAMM consider the needs of pets. The Company has grown consistently in the last year and if NettaVet’s clinical trials generate positive results, RAMM could see some purrific growth in the near future.


RAMM’s stock price opened at $1.04 today and is currently up to $1.08.

Related Posts

More on

Leave a Reply

Your email address will not be published. Required fields are marked *